• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过多种结合方式快速便捷地开发 PROTACs 的固相合成。

Development of Rapid and Facile Solid-Phase Synthesis of PROTACs via a Variety of Binding Styles.

机构信息

National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki, Kanagawa, 210-9501, Japan.

Graduate School of Medical Life Science, Yokohama City University 1-7-29, Yokohama, Kanagawa, 230-0045, Japan.

出版信息

ChemistryOpen. 2022 Jul;11(7):e202200131. doi: 10.1002/open.202200131.

DOI:10.1002/open.202200131
PMID:35822913
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9278092/
Abstract

Optimizing linker design is important for ensuring efficient degradation activity of proteolysis-targeting chimeras (PROTACs). Therefore, developing a straightforward synthetic approach that combines the protein-of-interest ligand (POI ligand) and the ligand for E3 ubiquitin ligase (E3 ligand) in various binding styles through a linker is essential for rapid PROTAC syntheses. Herein, a solid-phase approach for convenient PROTAC synthesis is presented. We designed azide intermediates with different linker lengths to which the E3 ligand, pomalidomide, is attached and performed facile PROTACs synthesis by forming triazole, amide, and urea bonds from the intermediates.

摘要

优化连接子设计对于确保蛋白水解靶向嵌合体(PROTAC)的降解活性至关重要。因此,开发一种直接的合成方法,通过连接子将目标蛋白配体(POI 配体)和 E3 泛素连接酶配体(E3 配体)以各种结合方式结合在一起,对于快速合成 PROTAC 至关重要。在此,提出了一种用于方便 PROTAC 合成的固相方法。我们设计了带有不同连接子长度的叠氮化物中间体,将 E3 配体泊马度胺连接到这些中间体上,并通过中间体形成三唑、酰胺和脲键,轻松地合成 PROTAC。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/9278092/cf12ae6c4d31/OPEN-11-e202200131-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/9278092/1c2ad5d702a2/OPEN-11-e202200131-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/9278092/1e1c116653a6/OPEN-11-e202200131-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/9278092/ca7c155040db/OPEN-11-e202200131-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/9278092/cf12ae6c4d31/OPEN-11-e202200131-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/9278092/1c2ad5d702a2/OPEN-11-e202200131-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/9278092/1e1c116653a6/OPEN-11-e202200131-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/9278092/ca7c155040db/OPEN-11-e202200131-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/9278092/cf12ae6c4d31/OPEN-11-e202200131-g005.jpg

相似文献

1
Development of Rapid and Facile Solid-Phase Synthesis of PROTACs via a Variety of Binding Styles.通过多种结合方式快速便捷地开发 PROTACs 的固相合成。
ChemistryOpen. 2022 Jul;11(7):e202200131. doi: 10.1002/open.202200131.
2
Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.开发用于合成具有多种E3配体的PROTAC的通用固相方法。
Bioorg Med Chem. 2023 May 15;86:117293. doi: 10.1016/j.bmc.2023.117293. Epub 2023 Apr 25.
3
A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions.在微型化条件下快速合成蛋白水解靶向嵌合体(Rapid-TAC)的平台。
Eur J Med Chem. 2022 Jun 5;236:114317. doi: 10.1016/j.ejmech.2022.114317. Epub 2022 Apr 1.
4
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.PROteolysis TArgeting Chimeras (PROTACs) 作为新兴的抗癌治疗药物。
Oncogene. 2020 Jun;39(26):4909-4924. doi: 10.1038/s41388-020-1336-y. Epub 2020 May 31.
5
E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points.成功的PROTACs中的E3连接酶配体:合成及连接点概述
Front Chem. 2021 Jul 5;9:707317. doi: 10.3389/fchem.2021.707317. eCollection 2021.
6
A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.VHL 招募型 PROTACs 合成连接子策略入门指南。
Bioorg Med Chem. 2023 Jun 6;88-89:117334. doi: 10.1016/j.bmc.2023.117334. Epub 2023 May 18.
7
Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.蛋白水解靶向嵌合体(PROTACs)在药物发现中的进展和展望。
Bioorg Chem. 2022 Aug;125:105848. doi: 10.1016/j.bioorg.2022.105848. Epub 2022 May 5.
8
CRBN ligand expansion for hematopoietic prostaglandin D synthase (H-PGDS) targeting PROTAC design and their in vitro ADME profiles.用于靶向造血前列腺素D合成酶(H-PGDS)的PROTAC设计的CRBN配体扩展及其体外ADME特性。
Bioorg Med Chem. 2023 Apr 15;84:117259. doi: 10.1016/j.bmc.2023.117259. Epub 2023 Mar 30.
9
Discovery of E3 Ligase Ligands for Target Protein Degradation.E3 连接酶配体用于靶蛋白降解的发现。
Molecules. 2022 Oct 2;27(19):6515. doi: 10.3390/molecules27196515.
10
Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic.PROTAC 介导的蛋白降解技术的最新进展:从实验室到临床。
Chembiochem. 2022 Jan 19;23(2):e202100270. doi: 10.1002/cbic.202100270. Epub 2021 Sep 23.

引用本文的文献

1
PROTAC-Based Antivirals for Respiratory Viruses: A Novel Approach for Targeted Therapy and Vaccine Development.基于PROTAC的呼吸道病毒抗病毒药物:靶向治疗和疫苗开发的新方法
Microorganisms. 2025 Jul 2;13(7):1557. doi: 10.3390/microorganisms13071557.
2
Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs.基于 Cereblon 的 PROTAC 的合成、生物学评价及临床试验
Commun Chem. 2025 Jul 29;8(1):218. doi: 10.1038/s42004-025-01598-9.
3
Methods to accelerate PROTAC drug discovery.加速PROTAC药物发现的方法。

本文引用的文献

1
Current strategies for the design of PROTAC linkers: a critical review.PROTAC连接子设计的当前策略:批判性综述。
Explor Target Antitumor Ther. 2020;1(5):273-312. doi: 10.37349/etat.2020.00018. Epub 2020 Oct 30.
2
Proteolysis-targeting chimeras (PROTACs) in cancer therapy.蛋白水解靶向嵌合体(PROTACs)在癌症治疗中的应用。
Mol Cancer. 2022 Apr 11;21(1):99. doi: 10.1186/s12943-021-01434-3.
3
Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity.酰胺到酯的取代作为优化 PROTAC 通透性和细胞活性的策略。
Biochem J. 2025 Jun 25;482(13):BCJ20243018. doi: 10.1042/BCJ20243018.
4
Targeted protein degradation: advances in drug discovery and clinical practice.靶向蛋白降解:药物发现和临床实践的进展。
Signal Transduct Target Ther. 2024 Nov 6;9(1):308. doi: 10.1038/s41392-024-02004-x.
5
Structure-activity relationship study of PROTACs against hematopoietic prostaglandin D synthase.针对造血前列腺素 D 合酶的 PROTACs 的构效关系研究
RSC Med Chem. 2022 Sep 23;13(12):1495-1503. doi: 10.1039/d2md00284a. eCollection 2022 Dec 14.
J Med Chem. 2021 Dec 23;64(24):18082-18101. doi: 10.1021/acs.jmedchem.1c01496. Epub 2021 Dec 9.
4
Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands.连接子连接点对 Cereblon 配体稳定性和新底物降解的影响。
ACS Med Chem Lett. 2021 Oct 18;12(11):1733-1738. doi: 10.1021/acsmedchemlett.1c00368. eCollection 2021 Nov 11.
5
Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via In Silico Design.通过计算机辅助设计发现一种高效且选择性的降解剂,靶向造血前列腺素 D 合酶。
J Med Chem. 2021 Nov 11;64(21):15868-15882. doi: 10.1021/acs.jmedchem.1c01206. Epub 2021 Oct 15.
6
Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation.靶向蛋白降解嵌合体(PROTACs)步入成熟:进入靶向蛋白降解的第三个十年。
RSC Chem Biol. 2021 Mar 19;2(3):725-742. doi: 10.1039/d1cb00011j.
7
Rapid synthesis of pomalidomide-conjugates for the development of protein degrader libraries.用于开发蛋白质降解剂文库的泊马度胺缀合物的快速合成。
Chem Sci. 2021 Feb 3;12(12):4519-4525. doi: 10.1039/d0sc05442a.
8
Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer.造血前列腺素D合酶降解诱导剂的研发
ACS Med Chem Lett. 2021 Jan 14;12(2):236-241. doi: 10.1021/acsmedchemlett.0c00605. eCollection 2021 Feb 11.
9
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.E3 连接酶配体用于 PROTACs:它们是如何被发现的,以及如何发现新的配体。
SLAS Discov. 2021 Apr;26(4):484-502. doi: 10.1177/2472555220965528. Epub 2020 Nov 3.
10
PROTACs: An Emerging Therapeutic Modality in Precision Medicine.蛋白水解靶向嵌合体(PROTACs):精准医学中的一种新兴治疗模式。
Cell Chem Biol. 2020 Aug 20;27(8):998-1014. doi: 10.1016/j.chembiol.2020.07.020. Epub 2020 Aug 13.